相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch et al.
CANCER TREATMENT REVIEWS (2021)
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao et al.
JAMA ONCOLOGY (2020)
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
Aena Patel et al.
CANCERS (2020)
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Qiao Li et al.
CLINICAL CANCER RESEARCH (2019)
Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Rasha M. Sareyeldin et al.
CANCERS (2019)
Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
Fengrui Xu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Pyrotinib or Lapatinib Combined With Capecitabine in HER2?Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel plus trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
Samuel A. Jacobs et al.
BREAST CANCER RESEARCH (2019)
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
Xin Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Fei Ma et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
H. Bonnefoi et al.
ANNALS OF ONCOLOGY (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Andre Robidoux et al.
LANCET ONCOLOGY (2013)
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
Valentina Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Trastuzumab: updatedmechanisms of action and resistance in breast cancer
Thuy Vu et al.
FRONTIERS IN ONCOLOGY (2012)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
分享论文
